Intellia Therapeutics, Inc. NTLA is developing its lead CRISPR-based, in vivo genome-editing candidate, nexiguran ziclumeran (nex-z, formerly known as NTLA-2001) for the treatment of transthyretin ...

Congress Wealth Management LLC DE purchased a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) in the 4th ...

Corient Private Wealth LLC lessened its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 4.0% during the ...

What’s really exciting about gene editing is precision and speed, says Pairwise cofounder and CEO Tom Adams, PhD.

Human extracellular matrices can be edited in their composition using the CRISPR/Cas9 system, leading to materials exhibiting tailored regenerative capacities.

Spread the love Introduction The biotechnology industry continues to be at the forefront of scientific innovation, driving ...

CRISPR leaders came together to celebrate the one-year anniversary of the Danaher-IGI Beacon for CRISPR Cures collaboration, ...

CRISPR technology has revolutionised genetic engineering, offering unprecedented precision in DNA editing with vast implications for medicine, agriculture and conservation. Yet, its power demands ...

CRISPR Therapeutics’ Julianne Bruno is hitting the exit in favor of external opportunities, marking the latest shakeup to the ...

Growers are exploring solutions to citrus greening. A crucial aspect is understanding consumer perceptions of genetic editing ...

Climate change is rapidly altering the agricultural landscape, leaving farmers scrambling to adjust. As temperatures rise, ...

At meeting on human embryo editing, CRISPR pioneer says science is a long way from knowing if germline DNA can be safely ...